Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide

Journal of Medicinal Chemistry

Volumn 48, Issue 4, 2005, Pages 1244-1250

  Irwin, Nigel ^a   Green, Brian D ^a   Gault, Victor A ^a   Greer, Brett ^b   Harriott, Patrick ^c   Bailey, Clifford J ^d   Flatt, Peter R ^a   O'Harte, Finbarr P M ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^d ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCOSE; INSULIN; PALMITIC ACID; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHINESE HAMSTER; CONTROLLED STUDY; DERIVATIZATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG DEGRADATION; DRUG HALF LIFE; FIBROBLAST; GENETIC TRANSFECTION; HYPERGLYCEMIA; INSULIN RELEASE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; CELL LINE; CRICETINAE; CRICETULUS; CYCLIC AMP; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTRIC INHIBITORY POLYPEPTIDE; HYPOGLYCEMIC AGENTS; INSULIN; MICE; MICE, OBESE; PALMITATES; PYRROLIDONECARBOXYLIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13944276310     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049262s     Document Type: Article

References (43)

1. Brown, J. C. Enteroinsular axis. In Gut Peptides: Biochemistry and Physiology; Dockray, G. J., Walsh, J. H., Eds.; Raven Press: New York, 1994; pp 765-784.
2. Creutzfeldt, W. The entero-insular axis in type 2 diabetes-Incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes 2001, 109, 288-303.
3. Trumper, A.; Trumper, K.; Trusheim, H.; Arnold, R.; Goke, B.; Horsch, D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 2001, 15, 1559-1570.
4. Trumper, A.; Trumper, K.; Horsch, D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J. Endocrinol. 2002, 174, 233-246.
5. Ehses, J. A.; Casilla, V. R.; Doty, T.; Pospisilik, J. A.; Winter, K. D.; Demuth, H. U.; Pederson, R. A.; McIntosh, C. H. S. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 2003, 144, 4433-4445.
6. Morgan, L. M. The metabolic role of GIP: Physiology and pathology. Biochem. Soc. Trans. 1996, 24, 585-591.
7. Gault, V. A.; Flatt, P. R.; O'Harte, F. P. M. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem. Biophys. Res. Commun. 2003, 308, 207-213.
8. Nauck, M. A.; Heimesaat, M. M.; Orskov, C.; Hoist, J. J.; Ebert, R.; Creutzfeldt, W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 1993, 93, 301-307.
9. Jones, I. R.; Owens, D. R.; Moody, A. J.; Luzio, S. D.; Morris, T.; Hayes, T. M. The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (noninsulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 1987, 30, 707-712.
10. Kjems, L. L.; Holst, J. J.; Volund, A.; Madsbad, S. The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52, 380-386.
11. Meier, J. J.; Nauck, M. A.; Siepmann, N.; Greulich, M.; Holst, J. J.; Deacon, C. F.; Schmidt, W. E.; Gallwitz, B. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 2003, 52, 1579-1585.
12. Meier, J. J.; Goetze, O.; Anstipp, J.; Hagemann, D.; Holst, J. J.; Schmidt, W. E.; Gallwitz, B.; Nauck, M. A. Gastric inhibitory polypeptide (GIP) does not inhibit gastric emptying in man. Am. J. Phys. Endocrinol. Metab. 2004, 286, E621-625.
13. Kieffer, T. J.; McIntosh, C. H. S.; Pederson, R. A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136, 3585-3596.
14. Brown, J. C.; Dahl, M.; Kwauk, S.; McIntosh, C. H. S.; Otte, S. C.; Pederson, R. A. Actions of GIP. Peptides 1981, 2, 241-245.
15. Gault, V. A.; Parker, J. C.; Harriott, P.; Flatt, P. R.; O'Harte, F. P. M. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide (GIP), GIP(3-42), is a GIP receptor antagonist in vivo. J. Endocrinol. 2002, 175, 525-533.
16. O'Harte, F. P. M.; Mooney, M. H.; Kelly, C. M. N.; Flatt, P. R. Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J. Endocrinol. 2000, 165, 639-648.
17. O'Harte, F. P. M.; Gault, V. A.; Parker, J. C.; Harriott, P.; Mooney, M. H.; Bailey, C. J.; Flatt, P. R. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of glucose-dependent insulinotropic poly-peptide: N-Acetyl-GIP and pGlu-GIP. Diabetologia 2002, 45, 1281-1291.
18. 1-modified enzyme resistant forms of GIP, is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem. J. 2002, 367, 913-920.
19. 2 substituted analogues of glucose-dependent insulinotropic polypeptide (GIP). J. Endocrinol. 2003, 176, 133-141.
20. 2]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 2002, 51, 656-661.
21. Lindsay, J. R.; Au, S. T. B.; Kelly, C. M. N.; O'Harte, F. P. M.; Flatt, P. R. A novel amino-terminally glycated analogue of glucose-dependent insulinotropic polypeptide (GIP), with a prolonged insulinotropic activity in type 2 diabetes mellitus. Diabetes 2002, 5, 1394.
22. Deacon, C. F.; Danielsen, P.; Klarskov, L.; Diesen, M.; Holst, J. J. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 2001, 50, 1588-1597.
23. Deacon, C. F.; Wamberg, S.; Bie, P.; Hughes, T. E.; Holst, J. J. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J. Endocrinol. 2002, 172, 355-362.
24. Meier, J. J.; Nauck, M. A.; Kranz, D.; Holst, J. J.; Deacon, C. F.; Gaeckler, D.; Schmidt, W. E.; Gallwitz, B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004, 53, 654-662.
25. Deacon, C. F.; Nauck, M. A.; Meier, J.; Hucking, K.; Holst, J. J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 2000, 85, 3575-3581.
26. Kurtzhals, P.; Havelund, S.; Jonassen, I.; Kiehr, B.; Larsen, U. D.; Ribel, U.; Markussen, J. Albumin binding of insulins acylated with fatty acids: Characterization of the ligand -protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 1995, 312, 725-731.
27. Holz, G. G.; Chepurny, O. G. Glucagon-like peptide-1 synthetic analogs: New therapeutic agents for use in the treatment of diabetes mellitus. Curr. Med. Chem. 2003, 10, 2471-2483.
28. 8-substituted GLP-1 analogues. Biol Chem. 2004, 385, 169-177.
29. Agersø, H.; Jensen, L. B.; Elbrønd, B.; Rolan, P.; Zdravkovic, M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy man. Diabetologia 2002, 45, 195-202.
30. Elbrond, B.; Jakobsen, G.; Larsen, S.; Agerso, H.; Jensen, L. B.; Rolan, P.; Sturis, J.; Hatorp, V.; Zdravkovic, M. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002, 25, 1398-1404.
31. Nauck, M. A.; Niederereichholz, U.; Ettler, R.; Holst, J. J.; Ørskov, C.; Ritzel, R.; Schmigel, W. H. Glucagon-like peptide-1 inhibition of gastric-emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 1997, 273, 981-988.
32. Hinke, S. A.; Manhart, S.; Pamir, N.; Demuth, H. U.; Gelling, R.; Pederson, R. A.; McIntosh, C. H. Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). Biochim. Biophys. Acta 2001, 1547, 143-155.
33. Bailey, C. J.; Flatt, P. R. Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obesity 1982, 6, 11-21.
34. Flatt, P. R.; Bailey, C. J. Development of glucose intolerance and impaired plasma insulin response to glucose in obese hyperglycaemic (ob/ob) mice. Horm. Metab. Res 1981, 13, 556-560.
35. Gault, V. A.; O'Harte, F. P. M.; Flatt, P. R. Glucose-dependent insulinotropic polypeptide (GIP): Anti-diabetic and anti-obesity potential? Neuropeptides 2003, 37, 253-263.
36. Fields, G. B.; Noble, R. L. Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 1990, 35, 161-214.
37. 13)GIP. Cell Biol. Int. 2003, 27, 41-46.
38. Gremlich, S.; Porret, A.; Hani, E. H.; Cherif, D.; Vionnet, N.; Froguel, P.; Thorens, B. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 1995, 44, 1202-1208.
39. McClenaghan, N. H.; Barnett, C. R.; Ah-Sing, E.; Abdel-Wahab, Y. H. A.; O'Harte, F. P. M.; Yoon, T. W.; Swanston-Flatt, S. K.; Flatt, P. R. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 1998, 45, 1132-1140.
40. Green, B. D.; Gault, V. A.; Mooney, M. H.; Irwin, N.; Bailey, C. J.; Harriott, P.; Greer, B.; Flatt, P. R.; O'Harte, F. P. M. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J. Mol. Endocrinol. 2003, 31, 529-540.
41. Stevens, J. F. Determination of glucose by an automatic analyser. Clin. Chem. Acta 1971, 32, 199-201.
42. Flatt, P. R.; Bailey, C. J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981, 20, 573-577.
43. Burington, R. S. Handbook of Mathematical Tables and Formulae; McGraw-Hill: New York, 1973.